Results 21 to 30 of about 4,565 (192)

Successful Treatment of Osimertinib Resistance in an EGFR-Mutant Lung Cancer Patient With a Rare STRN3-ALK Fusion Using Brigatinib and Osimertinib. [PDF]

Kaohsiung J Med Sci
The Kaohsiung Journal of Medical Sciences, Volume 41, Issue 7, July 2025.
Kuo CY, Lai WA, Lee TH, Yang CJ.
europepmc   +2 more sources

Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial. [PDF]

, 2023
INTRODUCTION: This open-label, phase 3 trial (ALTA-3; NCT03596866) compared efficacy and safety of brigatinib versus alectinib for ALK+ NSCLC after disease progression on crizotinib.
Ahn, M-J, Burotto, M, He, J, Kim, D-W, Lin, HM, Liu, G, Liu, X, Lu, S, Ma, X, Popat, S, Vincent, S, Yang, JC-H, Yin, J, Zhao, Y   +13 more
core   +1 more source

Early Onset Pulmonary Events and Management Strategies during the Treatment of 
ALK Positive NSCLC Patients with Brigatinib

Chinese Journal of Lung Cancer, 2023
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase and its rearrangements occur in non-small cell lung cancer (NSCLC), resulting in signal dysregulation in kinase domain.
Mingyi YANG, Weichi LUO, Qing ZHOU
doaj   +1 more source

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. [PDF]

, 2017
A challenge in precision medicine requires identification of actionable driver mutations. Critical to such effort is the deployment of sensitive and well-validated assays for mutation detection.
Ali, Siraj, Bergsland, Emily K, Bivona, Trever G, Damato, Bertil, Fogh, Shannon, Miller, Vincent A, Urisman, Anatoly, Wang, Victoria E, Wolfe, John, Young, Lauren   +9 more
core   +1 more source

Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor

AboutOpen, 2022
Objective: The aim of this economic evaluation was to assess the cost-utility of brigatinib versus alectinib in the treatment of naïve patients to anaplastic lymphoma kinase-positive advanced non-small cell lung cancer (ALK-positive aNSCLC) from the ...
Roberto Ravasio, Holly Cranmer, Izzie Kearns , Raffaella Viti, Simone Corinti   +4 more
doaj   +1 more source

Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

JTO Clinical and Research Reports, 2022
Introduction: We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK–rearrangement positive (ALK+) NSCLC. Methods: The phase 1/2 study evaluated brigatinib 30 to 300 mg/d in patients with advanced malignancies.
Scott N. Gettinger, MD, Rudolf M. Huber, MD, PhD, Dong-Wan Kim, MD, PhD, Lyudmila Bazhenova, MD, Karin Holmskov Hansen, MD, Marcello Tiseo, MD, Corey J. Langer, MD, FACP, Luis G. Paz-Ares Rodríguez, MD, PhD, Howard L. West, MD, Karen L. Reckamp, MD, MS, Glen J. Weiss, MD, Egbert F. Smit, MD, PhD, Maximilian J. Hochmair, MD, Sang-We Kim, MD, PhD, Myung-Ju Ahn, MD, PhD, Edward S. Kim, MD, FACP, Harry J.M. Groen, MD, PhD, Joanna Pye, MS, Yuyin Liu, PhD, Pingkuan Zhang, MD, Florin Vranceanu, MD, PhD, D. Ross Camidge, MD, PhD   +21 more
doaj   +1 more source

SEOM clinical guidelines for the treatment of non‑small cell lung cancer (2018) [PDF]

, 2018
Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic procedures such as liquid biopsy, treatments like immunotherapy, as well as deeper molecular
Carcereny, Enric, García, Y., García-Campelo, Rosario, Guirado, M., Insa, A., Juan, O., Majem, Margarita, Provencio, M., Reguart, Noemi, Trigo, J. M., Universitat Autònoma de Barcelona   +10 more
core   +4 more sources

The introduction of the Cancer Research UK Stratified Medicine Programme 2 (CRUK SMP2) in North East England; lessons learned and experience gained [PDF]

, 2016
Introduction: The CRUK SMP2 programme was set-up to evaluate the feasibility of performing large scale molecular analysis within the NHS on the (often small) diagnostic biopsies obtained in NSCLC.
Bettison, I, Black, F, Bolt, L, Bradshaw, A, Butler, R, Gardiner, J, Georgiadis, K, Greystoke, A, Hogarth, L, Hughes, A, Jaedicke, Katrin, Jamieson, D, Leaning, D, Mulvenna, P, Ness, T, Patterson, M, Simmons, T, Turner, D, Williams, I   +18 more
core   +1 more source

Patient-derived xenograft models of ALK+ ALCL reveal preclinical promise for therapy with brigatinib [PDF]

, 2023
Anaplastic large-cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by the oncogenic anaplastic lymphoma kinase (ALK), accounting for approximately 15% of all paediatric non-Hodgkin lymphoma.
Brugières, Laurence, Burke, G. A.Amos, Fend, Falko, Geoerger, Birgit, Johnston, Robert, Kenner, Lukas, Matthews, Jamie D., Merkel, Olaf, Montes-Mojarro, Ivonne A., Murray, Matthew J., Prokoph, Nina, Riguad, Charlotte, Trigg, Ricky M., Turner, Suzanne D.   +13 more
core   +1 more source

Simultaneous Quantification of Brigatinib and Brigatinib-Analog in Rat Plasma and Brain Homogenate by LC-MS/MS: Application to Comparative Pharmacokinetic and Brain Distribution Studies

International Journal of Analytical Chemistry, 2019
Brigatinib and brigatinib-analog are potent and selective ALK inhibitors with the similar structure. A simple and sensitive high-performance liquid chromatography with tandem mass spectrometry (LC-MS/MS) method for simultaneous determination of ...
Bo Li, Min Lu, Lei Jin, Maoen Zheng, Peilu Sun, Shanshan Lei, Shan Xiong, Suhong Chen   +7 more
doaj   +1 more source